Evidence map›Paper›PMID 26846108›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.

Tom Moritz, Simone Venz, Heike Junker, Sarah Kreuz, Reinhard Walther, Uwe Zimmermann

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Tom MoritzDepartment of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Simone VenzDepartment of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Heike JunkerDepartment of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany. hjunker@uni-greifswald.de.
Sarah KreuzDepartment of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Reinhard WaltherDepartment of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany. rwalther@uni-greifswald.de.
Uwe ZimmermannDepartment of Urology, Ernst Moritz Arndt University Greifswald, Greifswald, Germany.
Universität Greifswald · DEKing Abdullah University of Science and Technology · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumour protein D52 isoform 1 (PC-1), a member of the tumour protein D52 (TPD52) protein family, is androgen-regulated and prostate-specific expressed. Previous studies confirmed that PC-1 contributes to malignant progression in prostate cancer with an important role in castration-resistant stage. In the present work, we identified its impact in mechanisms leading to neuroendocrine (NE) transdifferentiation. We established for long-term PC-1 overexpression an inducible expression system derived from the prostate carcinoma cell line LNCaP. We observed that PC-1 overexpression itself initiates characteristics of neuroendocrine cells, but the effect was much more pronounced in the presence of the cytokine interleukin-6 (IL-6). Moreover, to our knowledge, this is the first report that treatment with IL-6 leads to a significant upregulation of PC-1 in LNCaP cells. Other TPD52 isoforms were not affected. Proceeding from this result, we conclude that PC-1 overexpression enhances the IL-6-mediated differentiation of LNCaP cells into a NE-like phenotype, noticeable by morphological changes and increased expression of typical NE markers, like chromogranin A, synaptophysin or beta-3 tubulin. Immunofluorescent staining of IL-6-treated PC-1-overexpressing LNCaP cells indicates a considerable PC-1 accumulation at the end of the long-branched neuron-like cell processes, which are typically formed by NE cells. Additionally, the experimentally initiated NE transdifferentiation correlates with the androgen receptor status, which was upregulated additively. In summary, our data provide evidence for an involvement of PC-1 in NE transdifferentiation, frequently associated with castration resistance, which is a major therapeutic challenge in the treatment of advanced prostate cancer.

Indexed as

AndrogensAdenocarcinomaAndrogen AntagonistsAntineoplastic Agents, HormonalBiomarkersCell Line, TumorCell TransdifferentiationHumansInterleukin-6MaleNeoplasm ProteinsNeoplasms, Hormone-DependentNeuroendocrine CellsProstatic NeoplasmsProtein DomainsProtein IsoformsAndrogen AntagonistsAndrogensAntineoplastic Agents, HormonalBiomarkersInterleukin-6Neoplasm ProteinsProtein IsoformsReceptors, AndrogenRecombinant Fusion ProteinsTPD52 protein, humanLNCaPNeuroendocrine transdifferentiationPC-1PrLZProstate cancerTPD52

Identifiers

PMID26846108
OpenAlexW2254777739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.